AbbVie’s Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs
With JAK inhibitors Under A Cloud Of Scrutiny Over Safety, FDA Seeks More Benefit-Risk Data
High-flying Rinvoq's ascent may be stalled by psoriatic arthritis approval delay • Source: Shutterstock 
